# US 2026/0076988 A1 · Timed alternate administration of decitabine and 5-azacytidine for cancer treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076988 A1
- Document ID: US20260076988A1
- Status: Published application
- Kind: A1
- Application number: 19/327,219
- Filed: 2025-09-12
- Published: 2026-03-19
- Earliest claimed: 2019-05-24
- Assignees: The Cleveland Clinic Foundation
- Applicants: The Cleveland Clinic Foundation
- Inventors: Yogen Saunthararajah; Vamsidhar Velcheti; Kai Kang; Xiaorong Gu; Rita Tohme
- Web page: https://patentgrep.com/patent/US20260076988A1

## CPC

- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61P 35/00: Antineoplastic agents
- G01N 33/5094: {for blood cell populations (red blood cells G01N33/80)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are compositions, systems, kits, and methods for treating a patient with cancer by alternate administration of decitabine and 5-azacytidine, or administration of decitabine two times per week on consecutive days, which is generally timed to bypass auto-dampening and exploit cross-priming. Such administration is combined with an inhibitor of the enzyme cytidine deaminase (e.g., tetrahydrouridine) that otherwise rapidly catabolizes decitabine and 5-azacytidine. In certain embodiments, the time between cycles of decitabine and 5-azacytidine administration is about three to four days or five to ten days.

## Claims

### Claim 1

A method of treating a human subject with cancer comprising, or consisting essentially of:
a) administering 5-15 mg/kg of a cytidine deaminase inhibitor to a human subject at a first time, wherein said human subject has cancer;
b) administering 0.07-0.4 mg/kg of decitabine to said subject at a second time, wherein said second time is between 0.5 and 7 hours after said first time;
c) administering 5-15 mg/kg of a cytidine deaminase inhibitor to said subject at a third time, wherein said third time is between 60 and 105 hours, or 106-240 hours, after said first time;
d) administering 0.5-4 mg/kg of 5-azacytidine to said subject at a fourth time, wherein said fourth time is: i) 0.5 and 7 hours after said third time, and ii) between 60 and 105 hours, or 106-240 hours, after said second time; and
e) repeating steps a)-d) at least once, wherein said administering in step a) is conducted between 60 and 105 hours, or 106-240 hours, after said fourth time.

### Claim 2 (depends on 1)

The method of claim 1, wherein said subject does not receive any decitabine or 5-azacytidine except at the times specified in steps b) and d) respectively.

### Claim 3 (depends on 1)

The method of claim 1, wherein said repeating steps a)-d) at least once comprises repeating steps a)-d) at last five times.

### Claim 4 (depends on 1)

The method of claim 1, wherein said repeating steps a)-d) at least once comprises repeating steps a)-d) at last twelve times.

### Claim 5 (depends on 1)

The method of claim 1, wherein said cancer is selected from the group consisting of: pancreatic cancer, a myeloid cancers, a lymphoid cancers, and small cell lung cancer.

### Claim 6 (depends on 1)

The method of claim 1, wherein said administering 5-15 mg/kg of said cytidine deaminase inhibitor in steps a) and c) comprises administering 9-11 mg/kg of said cytidine deaminase inhibitor.

### Claim 7 (depends on 1)

The method of claim 1, wherein said administering 0.07-0.4 mg/kg of decitabine comprises administering 0.1-0.3 mg/kg of said decitabine.

### Claim 8 (depends on 1)

The method of claim 1, wherein said administering 0.07-0.4 mg/kg of decitabine comprises administering 0.15-0.17 mg/kg of said decitabine.

### Claim 9 (depends on 1)

The method of claim 1, wherein said administering 0.5-4 mg/kg of 5-azacytidine comprises administering 1-3 mg/kg of said 5-azacytidine.

### Claim 10 (depends on 1)

The method of claim 1, wherein said administering 0.5-4 mg/kg of 5-azacytidine comprises administering 1.5-1.7 mg/kg of said 5-azacytidine.

### Claim 11 (depends on 1)

The method of claim 1, wherein said between 0.5 and 7 hours in step b) is between 1 and 5 hours.

### Claim 12 (depends on 1)

The method of claim 1, wherein said between 0.5 and 7 hours in step d) is between 1 and 5 hours.

### Claim 13 (depends on 1)

The method of claim 1, wherein said between 60 and 105 hours in step d) is between 70 and 98 hours.

### Claim 14 (depends on 1)

The method of claim 1, wherein said between 106 and 240 hours in step c) is between 160 and 170 hours.

### Claim 15 (depends on 1)

The method of claim 1, further comprising: administering said subject a composition comprising human granulocyte colony-stimulating factor (GCSF).

### Claim 16 (depends on 1)

The method of claim 1, further comprising: testing a sample from said subject to determine absolute neutrophil count (ANC).

### Claim 17 (depends on 16)

The method of claim 16, wherein said ANC is below 1.5×109, and said method further comprises administering said subject a composition comprising human granulocyte colony-stimulating factor (GCSF).

### Claim 18 (depends on 1)

The method of claim 1, wherein said subject does not receive any cytidine deaminase inhibitor except at the times specified in steps a) and c).

### Claim 19 (depends on 1)

The method of claim 1, wherein said cytidine deaminase inhibitor comprises tetrahydrouridine.

### Claim 20

A method of treating a human subject with cancer comprising, or consisting essentially of:
a) administering decitabine to said subject on day one;
b) administering decitabine to said subject on day two, wherein day two is the day immediately after said day one;
c) administering decitabine to said subject on day eight, wherein said day eight is seven days after said day one, and wherein said subject does not receive any decitabine between said administering in step b) and said administering in step c); and
d) administering decitabine to said subject on day nine, wherein said day nine is eight days after said day one.
